US20210330631A1 - Formulation of calcium channel blockers for treatment of sars-cov-2 induced covid-19 and other respiratory viruses through pulmonary delivery - Google Patents
Formulation of calcium channel blockers for treatment of sars-cov-2 induced covid-19 and other respiratory viruses through pulmonary delivery Download PDFInfo
- Publication number
- US20210330631A1 US20210330631A1 US17/234,112 US202117234112A US2021330631A1 US 20210330631 A1 US20210330631 A1 US 20210330631A1 US 202117234112 A US202117234112 A US 202117234112A US 2021330631 A1 US2021330631 A1 US 2021330631A1
- Authority
- US
- United States
- Prior art keywords
- formulation
- sars
- calcium
- cov
- verapamil hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- 238000009472 formulation Methods 0.000 title claims abstract description 62
- 230000002685 pulmonary effect Effects 0.000 title claims abstract description 26
- 208000025721 COVID-19 Diseases 0.000 title claims abstract description 24
- 238000011282 treatment Methods 0.000 title claims description 12
- 229940127291 Calcium channel antagonist Drugs 0.000 title abstract description 33
- 239000000480 calcium channel blocker Substances 0.000 title abstract description 32
- 241000700605 Viruses Species 0.000 title abstract description 25
- 230000000241 respiratory effect Effects 0.000 title abstract description 7
- DOQPXTMNIUCOSY-UHFFFAOYSA-N [4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl]-[2-(3,4-dimethoxyphenyl)ethyl]-methylazanium;chloride Chemical compound [H+].[Cl-].C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 DOQPXTMNIUCOSY-UHFFFAOYSA-N 0.000 claims abstract description 69
- 229960000881 verapamil hydrochloride Drugs 0.000 claims abstract description 69
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims abstract description 26
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000011575 calcium Substances 0.000 claims abstract description 25
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 25
- 241001678559 COVID-19 virus Species 0.000 claims abstract description 23
- 108090000312 Calcium Channels Proteins 0.000 claims abstract description 19
- 102000003922 Calcium Channels Human genes 0.000 claims abstract description 19
- 239000007922 nasal spray Substances 0.000 claims abstract description 17
- 229940097496 nasal spray Drugs 0.000 claims abstract description 17
- 230000010076 replication Effects 0.000 claims abstract description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 11
- 239000011780 sodium chloride Substances 0.000 claims abstract description 7
- 230000028956 calcium-mediated signaling Effects 0.000 claims abstract description 6
- 239000012153 distilled water Substances 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 230000000840 anti-viral effect Effects 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 18
- 210000004072 lung Anatomy 0.000 claims description 13
- 239000007921 spray Substances 0.000 claims description 9
- 102000003855 L-lactate dehydrogenase Human genes 0.000 claims description 8
- 108700023483 L-lactate dehydrogenases Proteins 0.000 claims description 8
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 claims description 8
- 102000003896 Myeloperoxidases Human genes 0.000 claims description 8
- 108090000235 Myeloperoxidases Proteins 0.000 claims description 8
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 8
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 8
- 229940118019 malondialdehyde Drugs 0.000 claims description 8
- 239000002158 endotoxin Substances 0.000 claims description 7
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 7
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 7
- 230000006378 damage Effects 0.000 claims description 6
- 230000001575 pathological effect Effects 0.000 claims description 6
- 229920002477 rna polymer Polymers 0.000 claims description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 210000005229 liver cell Anatomy 0.000 claims description 4
- 230000033001 locomotion Effects 0.000 claims description 4
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 3
- 102000000018 Chemokine CCL2 Human genes 0.000 claims description 3
- 238000002663 nebulization Methods 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 abstract description 9
- 239000006199 nebulizer Substances 0.000 abstract description 8
- 230000008685 targeting Effects 0.000 abstract description 5
- 208000025370 Middle East respiratory syndrome Diseases 0.000 abstract description 4
- 208000037847 SARS-CoV-2-infection Diseases 0.000 abstract description 4
- 206010022000 influenza Diseases 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 41
- 239000003814 drug Substances 0.000 description 20
- 229940079593 drug Drugs 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 108020000999 Viral RNA Proteins 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108091006146 Channels Proteins 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 241000315672 SARS coronavirus Species 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 208000001528 Coronaviridae Infections Diseases 0.000 description 3
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 3
- 241000711466 Murine hepatitis virus Species 0.000 description 3
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000012827 research and development Methods 0.000 description 3
- 210000005166 vasculature Anatomy 0.000 description 3
- 102000038650 voltage-gated calcium channel activity Human genes 0.000 description 3
- 108091023044 voltage-gated calcium channel activity Proteins 0.000 description 3
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 2
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000004612 Calcium-Transporting ATPases Human genes 0.000 description 2
- 108010017954 Calcium-Transporting ATPases Proteins 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229960004005 amlodipine besylate Drugs 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 229940127088 antihypertensive drug Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000004094 calcium homeostasis Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 229960003677 chloroquine Drugs 0.000 description 2
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940112141 dry powder inhaler Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- -1 isadipine Chemical compound 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000031852 maintenance of location in cell Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- NSVFSAJIGAJDMR-UHFFFAOYSA-N 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxido-1,3,2-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate Chemical compound CC=1NC(C)=C(C(=O)OCCN(CC=2C=CC=CC=2)C=2C=CC=CC=2)C(C=2C=C(C=CC=2)[N+]([O-])=O)C=1P1(=O)OCC(C)(C)CO1 NSVFSAJIGAJDMR-UHFFFAOYSA-N 0.000 description 1
- NMKSAYKQLCHXDK-UHFFFAOYSA-N 3,3-diphenyl-N-(1-phenylethyl)-1-propanamine Chemical compound C=1C=CC=CC=1C(C)NCCC(C=1C=CC=CC=1)C1=CC=CC=C1 NMKSAYKQLCHXDK-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- XTFPDGZNWTZCMF-DHZHZOJOSA-N 3-o-methyl 5-o-[(e)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC\C=C\C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 XTFPDGZNWTZCMF-DHZHZOJOSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- NCUCGYYHUFIYNU-UHFFFAOYSA-N Aranidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)=O)C1C1=CC=CC=C1[N+]([O-])=O NCUCGYYHUFIYNU-UHFFFAOYSA-N 0.000 description 1
- 241000557639 Araucaria bidwillii Species 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- ZKFQEACEUNWPMT-UHFFFAOYSA-N Azelnidipine Chemical compound CC(C)OC(=O)C1=C(C)NC(N)=C(C(=O)OC2CN(C2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZKFQEACEUNWPMT-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- KJEBULYHNRNJTE-DHZHZOJOSA-N Cinalong Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC\C=C\C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 KJEBULYHNRNJTE-DHZHZOJOSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- XQLWNAFCTODIRK-UHFFFAOYSA-N Gallopamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC(OC)=C(OC)C(OC)=C1 XQLWNAFCTODIRK-UHFFFAOYSA-N 0.000 description 1
- 108091006054 His-tagged proteins Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004016 L-Type Calcium Channels Human genes 0.000 description 1
- 108090000420 L-Type Calcium Channels Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 1
- 102000004129 N-Type Calcium Channels Human genes 0.000 description 1
- 108090000699 N-Type Calcium Channels Proteins 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 206010042600 Supraventricular arrhythmias Diseases 0.000 description 1
- 102000003691 T-Type Calcium Channels Human genes 0.000 description 1
- 108090000030 T-Type Calcium Channels Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229950007556 aranidipine Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- GOOXRYWLNNXLFL-UHFFFAOYSA-H azane oxygen(2-) ruthenium(3+) ruthenium(4+) hexachloride Chemical compound N.N.N.N.N.N.N.N.N.N.N.N.N.N.[O--].[O--].[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Ru+3].[Ru+3].[Ru+4] GOOXRYWLNNXLFL-UHFFFAOYSA-H 0.000 description 1
- 229950004646 azelnidipine Drugs 0.000 description 1
- 229960002992 barnidipine Drugs 0.000 description 1
- VXMOONUMYLCFJD-DHLKQENFSA-N barnidipine Chemical compound C1([C@@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@@H]2CN(CC=3C=CC=CC=3)CC2)=CC=CC([N+]([O-])=O)=C1 VXMOONUMYLCFJD-DHLKQENFSA-N 0.000 description 1
- 229960004916 benidipine Drugs 0.000 description 1
- QZVNQOLPLYWLHQ-ZEQKJWHPSA-N benidipine Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@H]2CN(CC=3C=CC=CC=3)CCC2)=CC=CC([N+]([O-])=O)=C1 QZVNQOLPLYWLHQ-ZEQKJWHPSA-N 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001601 blood-air barrier Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000008061 calcium-channel-blocking effect Effects 0.000 description 1
- MPBRYMWMMKKRGC-UHFFFAOYSA-M carbocyanin DBTC Chemical compound [Br-].C1=CC=CC2=C([N+](=C(C=C(C)C=C3N(C4=C5C=CC=CC5=CC=C4S3)CC)S3)CC)C3=CC=C21 MPBRYMWMMKKRGC-UHFFFAOYSA-M 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 229960003020 cilnidipine Drugs 0.000 description 1
- 229960003597 clevidipine Drugs 0.000 description 1
- KPBZROQVTHLCDU-GOSISDBHSA-N clevidipine Chemical compound CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@H]1C1=CC=CC(Cl)=C1Cl KPBZROQVTHLCDU-GOSISDBHSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 229950003102 efonidipine Drugs 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960002602 fendiline Drugs 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960000457 gallopamil Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008798 inflammatory stress Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 229960004340 lacidipine Drugs 0.000 description 1
- GKQPCPXONLDCMU-CCEZHUSRSA-N lacidipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C GKQPCPXONLDCMU-CCEZHUSRSA-N 0.000 description 1
- 238000007561 laser diffraction method Methods 0.000 description 1
- 229960004294 lercanidipine Drugs 0.000 description 1
- ZDXUKAKRHYTAKV-UHFFFAOYSA-N lercanidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZDXUKAKRHYTAKV-UHFFFAOYSA-N 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229960003963 manidipine Drugs 0.000 description 1
- ANEBWFXPVPTEET-UHFFFAOYSA-N manidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ANEBWFXPVPTEET-UHFFFAOYSA-N 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229960005366 nilvadipine Drugs 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 229960000227 nisoldipine Drugs 0.000 description 1
- 229960005425 nitrendipine Drugs 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229950004891 pranidipine Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- ADXCEOBGDCQCKM-UHFFFAOYSA-N quinoline-2,3-dione Chemical compound C1=CC=CC2=NC(=O)C(=O)C=C21 ADXCEOBGDCQCKM-UHFFFAOYSA-N 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 230000009447 viral pathogenesis Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000006394 virus-host interaction Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
Definitions
- the present invention relates to a formulation of a Calcium Channel Blocker (CCB) through pulmonary delivery using an inhaler, a nebulizer or any other similar delivery system against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) induced Coronavirus Disease 2019 (COVID-19), SARS, Middle East Respiratory Syndrome (MERS), Influenza and any other respiratory viruses thereof. More particularly, the invention relates to the formulation of calcium channel blockers preferably verapamil hydrochloride through pulmonary delivery as nasal spray for the treatment against COVID-19.
- SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2
- COVID-19 SARS-CoV-2
- MERS Middle East Respiratory Syndrome
- Influenza any other respiratory viruses thereof.
- the invention relates to the formulation of calcium channel blockers preferably verapamil hydrochloride through pulmonary delivery as nasal spray for the treatment against COVID-19.
- COVID-19 is a highly pathogenic respiratory disease, which exhibited an outbreak after its first appearance in Wuhan, China in December 2019.
- COVID-19 is caused by a novel coronavirus namely SARS-CoV, which causes respiratory illness with elevated fatality rate in patients with one or more of comorbidities such as obesity, hypertension and diabetes.
- SARS-CoV-2 causes respiratory illness and breathing complications with symptoms such as fever, cough, dyspnea etc. resulting in multiple organ syndrome and sometimes even death in severe cases similar to SARS-CoV.
- SARS-CoV-2 infection is observed as a continuation to the global spread of two previously unknown coronaviruses. The first known case of severe acute respiratory syndrome (SARS) was in November 2002 in China. This was followed by Middle East respiratory syndrome coronavirus (MERS-CoV) observed in April 2012.
- SARS severe acute respiratory syndrome
- MERS-CoV Middle East respiratory syndrome coronavirus
- SARS-CoV-2 is a positive single stranded Ribonucleic acid (RNA) virus with a genome length of approximately 30kb. SARS-CoV-2 infection is associated with human-to-human transmission, which is the reason for a rapid spread of the infection globally within a short period of time.
- the World Health Organization (WHO) declared COVID-19 as pandemic on 1 Mar. 2020. The report states that 2,463,357 confirmed cases of SARS-CoV-2 across 185 countries till date and 169,502 deaths have been reported and still counting. There are 41,575 deaths and over 778,000 positive cases reported in US alone.
- SARS-CoV-2 is not capable of replication by self and needs a host cell to replicate and multiply. SARS-CoV-2 exploits the environmental host cell for replication thus inducing host cell dysfunction. SARS-CoV-2-host interaction is the foundation for pathogenesis and associated with disease severity. The modulations of the intracellular environment have become an important strategy in antiviral drug discovery and development.
- SARS-CoV-2-host interaction results in the disruption of various cell functions affecting multiple cell processes.
- One of the processes disrupted by SARS-001-2-host interaction is calcium signaling. Calcium is essential for virus entry, viral gene replication, virion maturation and then its release from one cell to the other surrounding cells.
- the virus disturbs the host cell's calcium homeostasis as one of the strategies to modulate the host cell signaling in the favor of virus.
- the viruses hijack the host calcium channels and pumps leading to calcium imbalance in the host cells.
- Calcium as an important second messenger, mediates the sensor input and responses output for a majority of cellular processes such as stress responses, synaptic plasticity, imrnunodefenses, protein transport and endosome formation in mammals. It has been demonstrated that the host cell dysfunction following viral infection is accompanied by abnormal intracellular calcium concentration. SARS-CoV-2 and other like-viruses require intracellular system to achieve successful replication through multiple routes for example, viral proteins directly bind to calcium or disturb the membrane permeability for calcium by manipulating calcium apparatus.
- the host cell plasma membrane is the immediate target for the virus to enter the host cell.
- the plasma membrane comprises multiple channels and pumps that allow the entry of the virus into the host cell.
- targeting these calcium pumps or calcium channels such as voltage-gated calcium channels, store-operated channels, receptor operated channels, transient receptor potential ion channels and Calcium ATPase can be one of the targets to prevent the infection in host cells.
- MHV Mouse Hepatitis Virus
- HSV Herpes Simplex Virus
- HSV Human Immunodeficiency Virus
- MERS MERS
- MEW receptors function as calcium-dependent adhesion molecule and hence require calcium for utilization by MHV.
- the calcium channels and pumps are activated in a flexible and precise manner to generate specific calcium signaling, satisfying various spatiotemporal requirements.
- host cells modulate calcium-signaling components.
- viruses utilize host cell components to create a cellular environment that benefits viral lifecycle. Accordingly, targeting the calcium channels may be effective approach to combat SARS-CoV-2 infection.
- R&D Research and Development
- Calcium channel Mockers interrupt the movement of the calcium in cardiac and smooth muscle cells by blocking voltage-gated calcium channels.
- Calcium channel blockers are widely used in the treatment of hypertension, angina pectoris, supraventricular arrhythmias etc and recent studies indicate the efficacy of calcium channel blockers against various viruses such as bunya. viruses, arenaviruses and flaviviruses.
- the mode of administration of drug using a suitable formulation plays an important role in the efficacy of the drug. If the suitable mode is not selected, most of active ingredient shall be lost in the blood stream while reaching the site of action and may also require the higher dose. As SARS-CoV-2 is associated with pulmonary infection, the formulation shall be effective if directly targeted into lungs.
- the pulmonary administration is generally achieved through inhalers or nebulizers or any similar devices.
- the local therapy with pulmonary administration requires lower dose of the drug thus reducing the probability of occurrence of adverse effects in patients.
- Pulmonary delivery is an attractive route for systemic administration due to rapid absorption by the larger surface area of the alveolar region, the vasculature and thin air-blood barrier and the avoidance of first pass metabolism.
- the inhalers include meter dose inhalers or dry powder inhalers.
- the meter dose inhalers deliver a specific amount of medication to the lungs in the form of a short burst of aerosolized medicines that are usually self-administered by the patient during inhalation. These inhalers deliver a pre-set amount of medicine through mouth to the airways.
- the dry powder inhaler delivers medication to the lungs in the form of a dry powder.
- the dry powder inhaler drug formulations exhibit greater chemical stability than liquid formulations.
- a nebulizer is a delivery device in which the medication is fed into the nebulizer in the form of a liquid and the machine then turns this into a fine mist that makes it ideal for addressing respiratory disease and illness.
- US20050245502A1 titled “Treatments for viral infections” discloses a novel compositions comprising therapeutically effective amounts of an anticonvulsant component, such as phenytoin, with at least one calcium channel blocker component or metabolites thereof, a quinoline component, quinoline-quinone component or intermediates or derivatives such as chloroquine, in combination with a multivitamin component.
- an anticonvulsant component such as phenytoin
- the invention further comprises a quercetin component or one of its derivatives.
- the components combine and interact in a manner to effectively treat viruses by reducing viral activity in infected subjects.
- the Publication entitled “Calcium channel blocker amlodipine besylate is associated with reduced case fatality rate of COVID-19 patients with hypertension” by Zhang eta(discloses calcium channel blockers (CCBs), a type of anti-hypertension drugs that are widely used in the clinics that significantly inhibit the post-entry replication events of SARS-CoV-2 in vitro. It also discloses that the comparison with two other major types of anti-hypertension drugs, the angiotensin converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB), showed that only CCBs display significant anti-SARS-CoV-2 efficacy.
- ACEI angiotensin converting enzyme inhibitors
- ARB angiotensin II receptor blockers
- the Publication entitled “The SARS Coronavirus 3a protein hinds calcium in its cytoplasmic domain” by Rinki et. al discloses the expression and purification of the cytoplasmic domain of the 3a protein, called Cyto3a, as a recombinant His-tagged protein in E. coli .
- the calcium binding nature was established by performing various staining methods such as ruthenium red and stains-all. 45Ca overlay method was also done to further support the data.
- the results strongly suggest that the cytoplasmic domain of the 3a protein of SARS-CoV binds calcium in vitro, causing a change in protein conformation.
- the present invention overcomes the existing drawbacks by providing a formulation of verapamil hydrochloride for effective antiviral treatment against SARS-CoV-2.
- the present invention discloses a formulation of calcium channel blocker for treatment of against a novel coronavirus Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) induced Coronavirus Disease 2019 (COVID-19).
- the formulation comprises verapamil hydrochloride at a concentration in the range between 15 mg/mL and 25 mg/mL, sodium chloride at a concentration of 6.25 mg/mL and distilled water at a volume between q.s. to 1 mL.
- the formulation is administered as a nasal spray through pulmonary route.
- verapamil hydrochloride exhibited chemical stability at 60° C. for 33 weeks. These accelerated stability conditions are indicative of the room temperature stability of the nasal spray formulation for up to two years. There was no effect of pH on the chemical stability, but in the formulations with acidic pHs, the pH values increased with time. The pH is maintained without the use of any buffer. In addition, suitable preservatives accepted by US-FDA to be used to prevent microbial growth as it is a multiple dose formulation.
- the formulation is analyzed for antiviral activity in-vitro cell lines.
- the antiviral activity of different concentration of verapamil hydrochloride is analyzed in human liver cell line, which is grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 5% heat-inactivated fetal bovine serum.
- DMEM Dulbecco's Modified Eagle's Medium
- the antiviral activity is analyzed against novel SARS-COV-2. (USA-WA1/2020) isolated from an oropharyngeal swab from a patient in Washington, USA (BEI NR-52281).
- the isolated virus strain is amplified once in Vero E6 cells and had titers of 5 ⁇ 106 plaque-forming units (PFU)/mL.
- the parameters such as entry, replication of the virus is analyzed and the results indicated that verapamil hydrochloride is effective in inhibition of replication of SARS-CoV-2 through its action on calcium channels on the cell membrane and intracellular storage
- Verapamil hydrochloride at a concentration of 10 mg/kg exhibited anti-inflammatory activity in lipopolysaccharide-induced pathological damage in mice.
- the anti-inflammatory activity of verapamil hydrochloride is attributed to inhibition of the levels of Interleukin-1b (IL-1b), Tumor Necrosis Factor (TNF-a) and Monocyte Chemoattracant Protein-1 (MCP-1) in serum.
- IL-1b Interleukin-1b
- TNF-a Tumor Necrosis Factor
- MCP-1 Monocyte Chemoattracant Protein-1
- the antioxidant activity is due to inhibition of activities of Myeloperoxidase (MPO), Lactate Dehydrogenase (LDH) and Superoxide Dismutase (SOD), Malondialdehyde (MDA) content and lung wet/dry ratio in mouse.
- MPO Myeloperoxidase
- LDH Lactate Dehydrogenase
- SOD Superoxide Dismutase
- MDA Malondialdehyde
- Verapamil hydrochloride is investigated for antiviral activity in patients with Chronic obstructive pulmonary disease (COPD).
- Verapamil hydrochloride is administered as nasal spray and saline as placebo.
- Verapamil hydrochloride also improved correction of blood pH, blood oxygen pressure and oxygen ratio by maintaining high concentration in alveolar space and dilating the pulmonary vasculature selectivity. This indicates that verapamil hydrochloride is safe and does not produce any adverse effects in patients with COPD.
- the formulation of the present invention is administered through pulmonary delivery as a nasal spray using a spray device.
- the spray device has an ability to deliver the volume of 50 to 140 ⁇ l volume in the form of a spray.
- the droplet size is smaller than 10 ⁇ m the visual plume will be through the manual actuation.
- the pulmonary administration is simple and effective with lower dose requirement of verapamil hydrochloride with improved tolerance, patient compliance in addition to effective viral eradication.
- FIG. 1 illustrates the formulations of verapamil hydrochloride according to an embodiment of the invention
- FIG. 2 illustrates the results of the stability studies of formulations of verapamil hydrochloride at 60° C. for up to 33 days.
- FIG. 3 a illustrates the in-vitro antiviral activity of verapamil hydrochloride in SARS-COV-2 infected. Huh-7 cell line.
- FIG. 3 b illustrates reduction in cell viability in SARS-COV-2 infected Huh-7 cell line.
- FIG. 4 illustrates the effect of verapamil hydrochloride against lipopolysaccharide-induced pathological damage in mice.
- Replication refers to a process in which a cell duplicates into one or more molecules of DNA.
- Phenary Administration or inhalation refers to direct administration of medication into lungs using the inhalers, nebulizers or other suitable devices.
- the invention relates to a formulation of a calcium channel blocker for nasal delivery.
- the invention relates to a formulation of verapamil hydrochloride through nasal delivery against a novel coronavirus Severe Acute Respiratory Syndrome Coronavirus 2-induced COVID-19.
- Calcium channel blockers are effective in interrupting the calcium pumps or calcium channel by blocking the movement of calcium ions in the cells.
- the invention discloses a specific drug delivery system comprising a calcium channel blocker for pulmonary delivery,
- calcium channel blockers are broadly classified into dihydropyridine and non-dihydropyridines. According to an embodiment of the invention, targeting different types of calcium channels such as N-Type, L-type and T-type voltage dependent calcium channels may be potential target to fight against COVID-19.
- calcium channel blockers are screened for inhibition of calcium channels to identify the effective calcium channel blocker.
- the dihydropyridines such as amlodipine, aranidipine, azelnidipine, barnidipine, benidipine, cilnidipine, clevidipine, efonidipine, isadipine, lacidipine, lercanidipine, manidipine, nicardipine, nifedipine, nilvadipine, nimodipine, nisoldipine, nitrendipine, pranidipine are screened for the range of inhibition of various types of calcium channel blockers.
- the screening of di hydropyridines is aimed to standardize the dosage required to block the calcium channels effectively in addition to identify the effective calcium channel blocker.
- Dihydropyridines are used in the range between 10 mcg to 200 mg per dose and to be analyzed based on the severity of the infection.
- the non-dihydropyridine class of calcium channel blockers such as class of phenyl alkylamine including fendiline, gall opamil, verapamil are screened for antiviral activity through calcium channel inhibition.
- the class of benzodiazepines more preferably diltiazem is also screened for antiviral activity against SARS-CoV-2 virus.
- the non-dihydropyridine and benzodiazepines are used in the range between 10 mcg to 200 mg per dose.
- FIG. 1 illustrates the formulations of verapamil hydrochloride according to an embodiment of the invention.
- the formulation of the present invention comprises verapamil hydrochloride at a concentration between 15 mg/mL to 25 mg/mL, sodium chloride at a concentration of 6.25 mg/mL and distilled water at a volume between q.s. to 1 mL.
- the formulation is recommended for pulmonary delivery through nasal spray.
- the formulation is prepared with different concentrations of verapamil hydrochloride to analyze the stability at an optimum period of time.
- the formulations with varied concentration of verapamil hydrochloride is prepared in which the formulation 1 comprises verapamil hydrochloride at a concentration of 19.9 mg/mL at pH 5.13, the formulation 2 comprises verapamil hydrochloride at a concentration of 19.9 mg/mL at pH 6.09, the formulation 3 comprises verapamil hydrochloride at a concentration of 19.8 mg/mL at pH 4.63, the formulation 4 comprises verapamil hydrochloride at a concentration of 19.2 mg/mL at pH 5.61 and the formulation 5 comprises verapamil hydrochloride at a concentration of 20.0 mg/mL at 4.09.
- FIG. 2 illustrates the results of the stability studies of formulations of verapamil hydrochloride at 60° C.
- the stability of the formulation comprising various concentration of verapamil hydrochloride is studied at different time intervals at 0 days, 6, 14, 24 days and 33 days to analyze the stability of the formulation.
- the formulations are stored in 20-ml, injection vials at 60° C.
- the two extra peaks at 2.95 min and 4.25 min are also observed in the standard.
- no discoloration is observed in any of the samples after 2 weeks at 60° C.
- the pH values also did not change from 1-week.
- no new drug degradation products are observed in any of the five samples suggesting good stability of the formulation.
- verapamil hydrochloride is analyzed for in vitro antiviral activity in SARS-COV-2 infected cell line.
- FIG. 3 illustrates the in vitro antiviral activity of verapamil hydrochloride in SARS-COV-2 infected cell line.
- the antiviral activity of different concentration of verapamil hydrochloride is analyzed in human liver cell line.
- Human liver cells are grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 5% heat-inactivated fetal bovine serum.
- Viral RNA levels are analyzed by quantitative reverse transcription-polymerase chain reaction (qRT-PCR).
- RNA from cell culture supernatant is extracted using a Viral RNA Mini Kit and qRT-PCR is used to measure viral RNA levels using previously published primers and probes specific for the SARS-COV-2 namely 5′-CCGCTGCCCAACACAAG-3′as forward primer, 5′-CCACTAACCIFICTIFFGCAGACAT-3′ as reverse primer with 5′-/56-FAMIAGCCTACCTIZEN/TGACAAGCAATCAGACACTCAA/3IABkFQ/-3′ as a probe targeting the SARS-COV-2 Ni.
- Viral RNA copies are determined after comparison with a standard curve produced using serial 10-fold dilutions of SARS-COV-2 RNA.
- the cytotoxicity of verapamil hydrochloride in Hur cells infected with SARS-COV-2 is measured using trypan blue method and percentage cell numbers are quantified using trypan blue after 48 hours.
- SARS-COV-2 is isolated from oropharyngeal swab from a patient in Washington, USA and after isolation virus strain is amplified in Vero E6 cells to obtain titers of 5 ⁇ 106 plaque-forming units (PFU)/mL.
- Huh7 cells are pretreated with verapamil hydrochloride at a different concentration of 6.25, 12.5, 25, and 50 uM.
- Huh7 cells are infected with SARS-CoV-2 at a multiplicity of infection (MOI) of 0.1 for 1 hour, followed by the addition of increasing concentrations of verapamil hydrochloride at a different concentration of 6.25, 12.5, 25, and 50 uM and 0.1% DMSO is used as control.
- MOI multiplicity of infection
- the cell culture supernatants are collected at 48 hours after infection and viral RNA copies are measured by RT-PCR.
- FIG. 3 a illustrates the in vitro antiviral activity of verapamil hydrochloride in SARS-COV-2 infected cell line
- FIG. 3 b illustrates reduction in cell viability in SARS-COV-2 infected cell line treated with verapamil hydrochloride.
- Verapamil hydrochloride showed no significant toxicity against Huh7 cells at the used concentration at 48 hours. This interprets the in-vitro antiviral activity of verapamil hydrochloride.
- the in-vitro cell-based assay is performed using the CaCo-2 cell lines using DMSO as a solvent and suitable growth medium.
- Verapamil hydrochloride is used at a concentration in the range between 0.032 ⁇ g/ml. to 100 ⁇ g/ml.
- the assay includes M128533 as a positive control.
- the EC90 compound concentration that reduces viral replication by 90%
- the EC90 compound concentration that reduces viral replication by 90%
- for the positive control is estimated to be 11 ⁇ g/ml and for hydrochloride is found to be 6.9 ⁇ g/ml in inhibiting the 90% of the viral replication in the experimental conditions.
- SARS-COV2 potent anti-viral effect of verapamil hydrochloride through its unique calcium channel blocking mechanism.
- Verapamil hydrochloride exerts antiviral activity through modulation of an entry, replication and release of SARS-COV2 through its action on calcium channels on the cell membrane as well as intracellular storage on endoplasmic reticulum. Verapamil hydrochloride target the calcium channel and inhibit the movement of calcium thus halting the calcium signaling in the cell systems. Calcium plays an important role in the adherence, replication and multiplication in the host cell. Once the virus enters the host cell, it utilizes the components of the host cell for replication and results in disruption of the host cell mechanisms including the calcium homeostasis thus altering the signal transduction in the host cell for survival and multiplication of the virus.
- the various host cell calcium channels and pumps including different voltage gated calcium channels, store operated channels, receptor operated channels, transient receptor potential ion channels and Calcium-ATPase etc. mediate the mobilization of secondary metabolite calcium across the plasma membranes and subcellular organelles thus modulating the intracellular free calcium.
- the intracellular calcium and the calcium channels play an important role in the viral-host interaction and viral pathogenesis in the host cell. These calcium channels and pumps are disrupted due to viral invasion leading to imbalance of intracellular calcium. As a result of which the viral growth is enhanced affecting the host cell morbidity.
- the effect of verapamil hydrochloride is analyzed in lipopolysaccharide-induced pathological damage in mouse.
- the levels of interleukin-1b IL-1b IL-1b
- Tumor Necrosis Factor TNF- ⁇
- MCP-1 Monocyte Chemoattractant Protein-1
- MPO Myeloperoxidase
- LDH Lactate Dehydrogenase
- SOD Superoxide Dismutase
- MDA Malondialdehyde
- FIG. 4 illustrates the effect of verapamil hydrochloride against lipopolysaccharide-induced pathological damage in mice.
- Mice are treated with 5 mg/kg of lipopolysaccharide.
- verapamil hydrochloride is treated with verapamil hydrochloride at a concentration of 10mg,/kg, and saline as control and observed for 10 hours.
- the levels of IN-1b, TNF-a, MCP-1 in serum is analyzed using ELISA and activities of MPO, LDH, SOD and MDA is analyzed in addition to lung wet/dry ratio.
- the effect of verapamil hydrochloride on total cells, macrophages and neutrophils in Bronchoalveolar Lavage Fluid (BALF) is also analyzed.
- BALF Bronchoalveolar Lavage Fluid
- verapamil hydrochloride exhibited anti-inflammatory activity by reducing the serum levels of IN-1b, TNF-a, MCP-1 and total cells, macrophages and neutrophils in BALF.
- the activities of MPO. LDH, SOD and MDA levels are reduced in lung tissue in response to verapamil hydrochloride. This indicates the anti-inflammatory and antioxidant activity of verapamil hydrochloride in mice.
- Verapamil hydrochloride is analyzed for antiviral activity in patients with Chronic obstructive pulmonary disease (COPD).
- COPD Chronic obstructive pulmonary disease
- a double-blind placebo trial is conducted to analyze the effect of verapamil hydrochloride in patients admitted in Intensive Care Unit (ICU).
- Verapamil hydrochloride is administered as nasal spray and saline as placebo.
- Verapamil hydrochloride also improved correction of blood pH, blood oxygen pressure and oxygen ratio by maintaining high concentration in alveolar space and dilating the pulmonary vasculature selectivity. This indicates that verapamil hydrochloride is safe and does not induce any adverse effects in patients with COPD.
- verapamil hydrochloride is administered through pulmonary administration or inhalation using a nasal spray.
- the efficacy of a drug varies with the mode of administration and the drug may require more time to reach the site of action or may alter its efficacy while in the blood stream.
- the pharmacokinetics and the pharmacodynamics of the drug plays an important role in determining the efficacy of the drug.
- the mode of administration is very critical.
- Calcium channel blockers are administered. through pulmonary route, which directly targets the lung where the severity of the infection is high.
- direct pulmonary administration has an advantage for effective drug delivery without passing through the blood stream for a long time and decreasing the dosage due to direct administration.
- the pulmonary administration or inhalation of calcium channel blockers is achieved using unique drug delivery system such as inhalers or nebulizers.
- inhalers such as pressurized metered dose inhalers, dry powder inhalers, multi-dose liquid inhalers and soft-mist inhalers for pulmonary administration.
- small-volume nebulizer SVN
- breath-actuated jet nebulizer vibrating mesh nebulizer
- jet nebulizer with virtual valve technology perforated oscillating membrane
- deep tube oral spray are effective in delivering the calcium channel blockers as monotherapy or in combination for the treatment of COVID-19.
- the inhalers and nebulizers are simple and effective in pulmonary administration with lower dose requirement of drug.
- the pulmonary administration results in delivering precise and consistent doses to a targeted region in the lungs and maintain the stability of the delivered drugs.
- the pulomary administration of the calcium channel blockers or antagonists requires only low dose of the drug due to its local pharmacological action in lungs compared to oral or any other route of administration.
- the pulomary administration is also associated with improved tolerance, patient compliance and also with effective viral eradication.
- verapamil hydrochloride is administered as nasal spray with a concentration in the range between 15 mg/L to 20 mg/mL.
- the actuator has the ability to deliver less concentration of the drug i.e. 2.5 mg/actuation or spray.
- the nasal spray has an ability to deliver up to 140 ul of the solution and the concentration administered is 2.5 mg/125 ul.
- the nasal spray of the formulation of the present invention is administrated through a spray device.
- the spray device has capability of administering dose volume in the range between 50 ⁇ l to 140 ⁇ l of the formulation with a droplet size less than 10 ⁇ m as tested by laser diffraction method.
- the nasal spray of verapamil hydrochloride reduces the dose requirement as targeted delivery in nose which allows the entry of the virus and passage through upper respiratory and then lower respiratory tract.
- the nasal spray is also associated with ease of administration, improved patient compliance, self-administration without requirement of health professional and. is also cost-effective.
- the formulation of the invention may be useful as add-on therapy to the recommended standard of care for the patients who are moderately severe thus improving the disease outcome in patients.
- the treatment may be administered to patients who are tested positive for SARS-COV-2 virus at an early stage as well as those who have serious pneumonia like complications leading to Acute Respiratory Distress Syndrome (ARDS).
- ARDS Acute Respiratory Distress Syndrome
Abstract
The invention relates to a formulation of Calcium Channel Blocker (CCB) through pulmonary delivery using an inhaler, nebulizer or a similar delivery system against a novel coronavirus Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) induced COVID-19 and other respiratory viruses such as influenza, SARS, MERS etc. The formulation comprises verapamil hydrochloride at a concentration between 15 mg/mL and 25 mg/mL, sodium chloride at a concentration of 6.25 mg/mL and distilled water at a volume between q.s. to 1 mL. The formulation is administered as pulmonary delivery through nasal spray. The calcium signaling plays an important role in entry and replication of virus in the host cell and hence targeting the calcium channels or pumps that mediate the mobility of the intracellular calcium is an effective target for SARS-CoV-2 infection.
Description
- This application claims the benefit of U.S. Provisional Application No. 63/016,595 filed Apr. 28, 2020, all of which is incorporated herein by reference in its entirety.
- The present invention relates to a formulation of a Calcium Channel Blocker (CCB) through pulmonary delivery using an inhaler, a nebulizer or any other similar delivery system against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) induced Coronavirus Disease 2019 (COVID-19), SARS, Middle East Respiratory Syndrome (MERS), Influenza and any other respiratory viruses thereof. More particularly, the invention relates to the formulation of calcium channel blockers preferably verapamil hydrochloride through pulmonary delivery as nasal spray for the treatment against COVID-19.
- COVID-19 is a highly pathogenic respiratory disease, which exhibited an outbreak after its first appearance in Wuhan, China in December 2019. COVID-19 is caused by a novel coronavirus namely SARS-CoV, which causes respiratory illness with elevated fatality rate in patients with one or more of comorbidities such as obesity, hypertension and diabetes.
- SARS-CoV-2 causes respiratory illness and breathing complications with symptoms such as fever, cough, dyspnea etc. resulting in multiple organ syndrome and sometimes even death in severe cases similar to SARS-CoV. SARS-CoV-2 infection is observed as a continuation to the global spread of two previously unknown coronaviruses. The first known case of severe acute respiratory syndrome (SARS) was in November 2002 in China. This was followed by Middle East respiratory syndrome coronavirus (MERS-CoV) observed in April 2012.
- SARS-CoV-2 is a positive single stranded Ribonucleic acid (RNA) virus with a genome length of approximately 30kb. SARS-CoV-2 infection is associated with human-to-human transmission, which is the reason for a rapid spread of the infection globally within a short period of time. The World Health Organization (WHO) declared COVID-19 as pandemic on 1 Mar. 2020. The report states that 2,463,357 confirmed cases of SARS-CoV-2 across 185 countries till date and 169,502 deaths have been reported and still counting. There are 41,575 deaths and over 778,000 positive cases reported in US alone.
- SARS-CoV-2 is not capable of replication by self and needs a host cell to replicate and multiply. SARS-CoV-2 exploits the environmental host cell for replication thus inducing host cell dysfunction. SARS-CoV-2-host interaction is the foundation for pathogenesis and associated with disease severity. The modulations of the intracellular environment have become an important strategy in antiviral drug discovery and development.
- SARS-CoV-2-host interaction results in the disruption of various cell functions affecting multiple cell processes. One of the processes disrupted by SARS-001-2-host interaction is calcium signaling. Calcium is essential for virus entry, viral gene replication, virion maturation and then its release from one cell to the other surrounding cells. The virus disturbs the host cell's calcium homeostasis as one of the strategies to modulate the host cell signaling in the favor of virus. Literally, the viruses hijack the host calcium channels and pumps leading to calcium imbalance in the host cells.
- Calcium as an important second messenger, mediates the sensor input and responses output for a majority of cellular processes such as stress responses, synaptic plasticity, imrnunodefenses, protein transport and endosome formation in mammals. It has been demonstrated that the host cell dysfunction following viral infection is accompanied by abnormal intracellular calcium concentration. SARS-CoV-2 and other like-viruses require intracellular system to achieve successful replication through multiple routes for example, viral proteins directly bind to calcium or disturb the membrane permeability for calcium by manipulating calcium apparatus.
- The host cell plasma membrane is the immediate target for the virus to enter the host cell. The plasma membrane comprises multiple channels and pumps that allow the entry of the virus into the host cell. Hence, targeting these calcium pumps or calcium channels such as voltage-gated calcium channels, store-operated channels, receptor operated channels, transient receptor potential ion channels and Calcium ATPase can be one of the targets to prevent the infection in host cells.
- It is also observed that intracellular calcium and phospholipase signaling plays an important role in the pathogenesis of Mouse Hepatitis Virus (MHV), influenza, Herpes Simplex Virus (HSV), Human Immunodeficiency Virus (HIV), MERS etc. MEW receptors function as calcium-dependent adhesion molecule and hence require calcium for utilization by MHV. Further, the calcium channels and pumps are activated in a flexible and precise manner to generate specific calcium signaling, satisfying various spatiotemporal requirements. During the viral infection, host cells modulate calcium-signaling components. On the other hand, viruses utilize host cell components to create a cellular environment that benefits viral lifecycle. Accordingly, targeting the calcium channels may be effective approach to combat SARS-CoV-2 infection.
- As on date, there are no effective formulations, drugs or treatment approach against COVID-19. However, there are global initiatives to overcome the pandemic and WHO has executed a Research and Development (R&D) blueprint, which is a global strategy and preparedness plan that allows the rapid activation of R&D activities during pandemics. The objective of blueprint is to fast-track the availability of effective diagnostic tests, vaccines and medicines that are accessible and avert large scale crisis globally.
- Calcium channel Mockers interrupt the movement of the calcium in cardiac and smooth muscle cells by blocking voltage-gated calcium channels. Calcium channel blockers are widely used in the treatment of hypertension, angina pectoris, supraventricular arrhythmias etc and recent studies indicate the efficacy of calcium channel blockers against various viruses such as bunya. viruses, arenaviruses and flaviviruses.
- The mode of administration of drug using a suitable formulation plays an important role in the efficacy of the drug. If the suitable mode is not selected, most of active ingredient shall be lost in the blood stream while reaching the site of action and may also require the higher dose. As SARS-CoV-2 is associated with pulmonary infection, the formulation shall be effective if directly targeted into lungs.
- The pulmonary administration is generally achieved through inhalers or nebulizers or any similar devices. The local therapy with pulmonary administration requires lower dose of the drug thus reducing the probability of occurrence of adverse effects in patients. Pulmonary delivery is an attractive route for systemic administration due to rapid absorption by the larger surface area of the alveolar region, the vasculature and thin air-blood barrier and the avoidance of first pass metabolism.
- The inhalers include meter dose inhalers or dry powder inhalers. The meter dose inhalers deliver a specific amount of medication to the lungs in the form of a short burst of aerosolized medicines that are usually self-administered by the patient during inhalation. These inhalers deliver a pre-set amount of medicine through mouth to the airways. The dry powder inhaler delivers medication to the lungs in the form of a dry powder. The dry powder inhaler drug formulations exhibit greater chemical stability than liquid formulations. A nebulizer is a delivery device in which the medication is fed into the nebulizer in the form of a liquid and the machine then turns this into a fine mist that makes it ideal for addressing respiratory disease and illness.
- The Patent Application No. US20050245502A1 titled “Treatments for viral infections” discloses a novel compositions comprising therapeutically effective amounts of an anticonvulsant component, such as phenytoin, with at least one calcium channel blocker component or metabolites thereof, a quinoline component, quinoline-quinone component or intermediates or derivatives such as chloroquine, in combination with a multivitamin component. In preferred embodiments, the invention further comprises a quercetin component or one of its derivatives. The components combine and interact in a manner to effectively treat viruses by reducing viral activity in infected subjects.
- The Publication entitled “Calcium channel blocker amlodipine besylate is associated with reduced case fatality rate of COVID-19 patients with hypertension” by Zhang eta(discloses calcium channel blockers (CCBs), a type of anti-hypertension drugs that are widely used in the clinics that significantly inhibit the post-entry replication events of SARS-CoV-2 in vitro. It also discloses that the comparison with two other major types of anti-hypertension drugs, the angiotensin converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB), showed that only CCBs display significant anti-SARS-CoV-2 efficacy. The combined treatment with chloroquine and CCBs significantly enhanced the anti-SARS-CoV-2 efficacy. The retrospective clinical investigation of COVID-19 patients revealed that the oral administration of CCB amlodipine besylate distinctly reduced the case fatality rate of patients with hypertension.
- The Publication entitled “The SARS Coronavirus 3a protein hinds calcium in its cytoplasmic domain” by Rinki et. al discloses the expression and purification of the cytoplasmic domain of the 3a protein, called Cyto3a, as a recombinant His-tagged protein in E. coli. The calcium binding nature was established by performing various staining methods such as ruthenium red and stains-all. 45Ca overlay method was also done to further support the data. The studies clearly indicate a significant change in the conformation of the Cyto3a protein after binding with calcium. The results strongly suggest that the cytoplasmic domain of the 3a protein of SARS-CoV binds calcium in vitro, causing a change in protein conformation.
- As the outbreak of COVID-19 grapples the human population, an urgent need to identify the medical strategies to combat the virus is growing. There are numerous studies disclosing the involvement of calcium channels or pumps in the replication of the viruses but lacks the efficacy due to improper or ineffective administration of the drug,
- Hence, in order to overcome the disadvantages that exist in the state of the art, there is need for a formulation along with an effective mode of delivery to block the entry and replication of the virus, which is effective against SARS-CoV-2 virus and COVID-19 in human.
- The present invention overcomes the existing drawbacks by providing a formulation of verapamil hydrochloride for effective antiviral treatment against SARS-CoV-2.
- The present invention discloses a formulation of calcium channel blocker for treatment of against a novel coronavirus Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) induced Coronavirus Disease 2019 (COVID-19). The formulation comprises verapamil hydrochloride at a concentration in the range between 15 mg/mL and 25 mg/mL, sodium chloride at a concentration of 6.25 mg/mL and distilled water at a volume between q.s. to 1 mL. The formulation is administered as a nasal spray through pulmonary route.
- The formulation of verapamil hydrochloride exhibited chemical stability at 60° C. for 33 weeks. These accelerated stability conditions are indicative of the room temperature stability of the nasal spray formulation for up to two years. There was no effect of pH on the chemical stability, but in the formulations with acidic pHs, the pH values increased with time. The pH is maintained without the use of any buffer. In addition, suitable preservatives accepted by US-FDA to be used to prevent microbial growth as it is a multiple dose formulation.
- The formulation is analyzed for antiviral activity in-vitro cell lines. The antiviral activity of different concentration of verapamil hydrochloride is analyzed in human liver cell line, which is grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 5% heat-inactivated fetal bovine serum. The antiviral activity is analyzed against novel SARS-COV-2. (USA-WA1/2020) isolated from an oropharyngeal swab from a patient in Washington, USA (BEI NR-52281). The isolated virus strain is amplified once in Vero E6 cells and had titers of 5×106 plaque-forming units (PFU)/mL. The parameters such as entry, replication of the virus is analyzed and the results indicated that verapamil hydrochloride is effective in inhibition of replication of SARS-CoV-2 through its action on calcium channels on the cell membrane and intracellular storage on endoplasmic reticulum.
- Verapamil hydrochloride at a concentration of 10 mg/kg exhibited anti-inflammatory activity in lipopolysaccharide-induced pathological damage in mice. The anti-inflammatory activity of verapamil hydrochloride is attributed to inhibition of the levels of Interleukin-1b (IL-1b), Tumor Necrosis Factor (TNF-a) and Monocyte Chemoattracant Protein-1 (MCP-1) in serum. Verapamil hydrochloride at a concentration of 10 mg/kg exhibited antioxidant activity in lipopolysaccharide-induced pathological damage in mice. The antioxidant activity is due to inhibition of activities of Myeloperoxidase (MPO), Lactate Dehydrogenase (LDH) and Superoxide Dismutase (SOD), Malondialdehyde (MDA) content and lung wet/dry ratio in mouse.
- Verapamil hydrochloride is investigated for antiviral activity in patients with Chronic obstructive pulmonary disease (COPD). Verapamil hydrochloride is administered as nasal spray and saline as placebo. The results indicated that verapamil hydrochloride increased oxygen saturation from 91.2±12.15 to 95.75±14.57 in patients after inhalation. Verapamil hydrochloride also improved correction of blood pH, blood oxygen pressure and oxygen ratio by maintaining high concentration in alveolar space and dilating the pulmonary vasculature selectivity. This indicates that verapamil hydrochloride is safe and does not produce any adverse effects in patients with COPD.
- The formulation of the present invention is administered through pulmonary delivery as a nasal spray using a spray device. The spray device has an ability to deliver the volume of 50 to 140 μl volume in the form of a spray. The droplet size is smaller than 10 μm the visual plume will be through the manual actuation. The pulmonary administration is simple and effective with lower dose requirement of verapamil hydrochloride with improved tolerance, patient compliance in addition to effective viral eradication.
-
FIG. 1 illustrates the formulations of verapamil hydrochloride according to an embodiment of the invention, -
FIG. 2 illustrates the results of the stability studies of formulations of verapamil hydrochloride at 60° C. for up to 33 days. -
FIG. 3a illustrates the in-vitro antiviral activity of verapamil hydrochloride in SARS-COV-2 infected. Huh-7 cell line. -
FIG. 3b illustrates reduction in cell viability in SARS-COV-2 infected Huh-7 cell line. -
FIG. 4 illustrates the effect of verapamil hydrochloride against lipopolysaccharide-induced pathological damage in mice. - In order to more clearly and concisely describe and point out the subject matter of the claimed invention, the following definitions are provided for specific terms, which are used in the following written description.
- The term “Replication” refers to a process in which a cell duplicates into one or more molecules of DNA.
- The term “Pulmonary Administration or inhalation” refers to direct administration of medication into lungs using the inhalers, nebulizers or other suitable devices.
- The invention relates to a formulation of a calcium channel blocker for nasal delivery. The invention relates to a formulation of verapamil hydrochloride through nasal delivery against a novel coronavirus Severe Acute Respiratory Syndrome Coronavirus 2-induced COVID-19.
- Calcium channel blockers are effective in interrupting the calcium pumps or calcium channel by blocking the movement of calcium ions in the cells. The invention discloses a specific drug delivery system comprising a calcium channel blocker for pulmonary delivery,
- Generally, calcium channel blockers are broadly classified into dihydropyridine and non-dihydropyridines. According to an embodiment of the invention, targeting different types of calcium channels such as N-Type, L-type and T-type voltage dependent calcium channels may be potential target to fight against COVID-19.
- According to another embodiment of the invention, calcium channel blockers are screened for inhibition of calcium channels to identify the effective calcium channel blocker. The dihydropyridines such as amlodipine, aranidipine, azelnidipine, barnidipine, benidipine, cilnidipine, clevidipine, efonidipine, isadipine, lacidipine, lercanidipine, manidipine, nicardipine, nifedipine, nilvadipine, nimodipine, nisoldipine, nitrendipine, pranidipine are screened for the range of inhibition of various types of calcium channel blockers.
- The screening of di hydropyridines is aimed to standardize the dosage required to block the calcium channels effectively in addition to identify the effective calcium channel blocker.
- Dihydropyridines are used in the range between 10 mcg to 200 mg per dose and to be analyzed based on the severity of the infection.
- The non-dihydropyridine class of calcium channel blockers such as class of phenyl alkylamine including fendiline, gall opamil, verapamil are screened for antiviral activity through calcium channel inhibition. In addition, the class of benzodiazepines more preferably diltiazem is also screened for antiviral activity against SARS-CoV-2 virus. The non-dihydropyridine and benzodiazepines are used in the range between 10 mcg to 200 mg per dose.
-
FIG. 1 illustrates the formulations of verapamil hydrochloride according to an embodiment of the invention. The formulation of the present invention comprises verapamil hydrochloride at a concentration between 15 mg/mL to 25 mg/mL, sodium chloride at a concentration of 6.25 mg/mL and distilled water at a volume between q.s. to 1 mL. The formulation is recommended for pulmonary delivery through nasal spray. - According to an embodiment of an invention, the formulation is prepared with different concentrations of verapamil hydrochloride to analyze the stability at an optimum period of time. The formulations with varied concentration of verapamil hydrochloride is prepared in which the
formulation 1 comprises verapamil hydrochloride at a concentration of 19.9 mg/mL at pH 5.13, theformulation 2 comprises verapamil hydrochloride at a concentration of 19.9 mg/mL at pH 6.09, theformulation 3 comprises verapamil hydrochloride at a concentration of 19.8 mg/mL at pH 4.63, theformulation 4 comprises verapamil hydrochloride at a concentration of 19.2 mg/mL at pH 5.61 and theformulation 5 comprises verapamil hydrochloride at a concentration of 20.0 mg/mL at 4.09. -
FIG. 2 illustrates the results of the stability studies of formulations of verapamil hydrochloride at 60° C. The stability of the formulation comprising various concentration of verapamil hydrochloride is studied at different time intervals at 0 days, 6, 14, 24 days and 33 days to analyze the stability of the formulation. The formulations are stored in 20-ml, injection vials at 60° C. The results indicated that formulation did not result in any discoloration after 6 days at 60° C. in any of the samples. However, there was change in pH due to acidic region. The two extra peaks at 2.95 min and 4.25 min are also observed in the standard. Further, no discoloration is observed in any of the samples after 2 weeks at 60° C. The pH values also did not change from 1-week. In addition, no new drug degradation products are observed in any of the five samples suggesting good stability of the formulation. - The stability studies indicates that the formulations are stable at 60° C. for 33 days, which in turn translate to a stability of around 2 years at 25° C. Further, there was no effect of pH on the chemical stability.
- According to another embodiment of the invention, verapamil hydrochloride is analyzed for in vitro antiviral activity in SARS-COV-2 infected cell line.
-
FIG. 3 illustrates the in vitro antiviral activity of verapamil hydrochloride in SARS-COV-2 infected cell line. The antiviral activity of different concentration of verapamil hydrochloride is analyzed in human liver cell line. Human liver cells are grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 5% heat-inactivated fetal bovine serum. Viral RNA levels are analyzed by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). RNA from cell culture supernatant is extracted using a Viral RNA Mini Kit and qRT-PCR is used to measure viral RNA levels using previously published primers and probes specific for the SARS-COV-2 namely 5′-CCGCTGCCCAACACAAG-3′as forward primer, 5′-CCACTAACCIFICTIFFGCAGACAT-3′ as reverse primer with 5′-/56-FAMIAGCCTACCTIZEN/TGACAAGCAATCAGACACTCAA/3IABkFQ/-3′ as a probe targeting the SARS-COV-2 Ni. Viral RNA copies are determined after comparison with a standard curve produced using serial 10-fold dilutions of SARS-COV-2 RNA. - The cytotoxicity of verapamil hydrochloride in Hur cells infected with SARS-COV-2 is measured using trypan blue method and percentage cell numbers are quantified using trypan blue after 48 hours. SARS-COV-2 is isolated from oropharyngeal swab from a patient in Washington, USA and after isolation virus strain is amplified in Vero E6 cells to obtain titers of 5×106 plaque-forming units (PFU)/mL. Huh7 cells are pretreated with verapamil hydrochloride at a different concentration of 6.25, 12.5, 25, and 50 uM. Further, Huh7 cells are infected with SARS-CoV-2 at a multiplicity of infection (MOI) of 0.1 for 1 hour, followed by the addition of increasing concentrations of verapamil hydrochloride at a different concentration of 6.25, 12.5, 25, and 50 uM and 0.1% DMSO is used as control. The cell culture supernatants are collected at 48 hours after infection and viral RNA copies are measured by RT-PCR.
-
FIG. 3a illustrates the in vitro antiviral activity of verapamil hydrochloride in SARS-COV-2 infected cell line andFIG. 3b illustrates reduction in cell viability in SARS-COV-2 infected cell line treated with verapamil hydrochloride. The results indicated that the treatment of cells with verapamil hydrochloride resulted in a dose-dependent reduction in the viral RNA in the supernatant compared to the DMSO at 48 hours after infection. Verapamil hydrochloride showed no significant toxicity against Huh7 cells at the used concentration at 48 hours. This interprets the in-vitro antiviral activity of verapamil hydrochloride. - The in-vitro cell-based assay is performed using the CaCo-2 cell lines using DMSO as a solvent and suitable growth medium. Verapamil hydrochloride is used at a concentration in the range between 0.032 μg/ml. to 100 μg/ml. The assay includes M128533 as a positive control. The EC90 (compound concentration that reduces viral replication by 90%) for the positive control is estimated to be 11 μg/ml and for hydrochloride is found to be 6.9 μg/ml in inhibiting the 90% of the viral replication in the experimental conditions. This experiment indicates potent anti-viral (SARS-COV2) effect of verapamil hydrochloride through its unique calcium channel blocking mechanism.
- Verapamil hydrochloride exerts antiviral activity through modulation of an entry, replication and release of SARS-COV2 through its action on calcium channels on the cell membrane as well as intracellular storage on endoplasmic reticulum. Verapamil hydrochloride target the calcium channel and inhibit the movement of calcium thus halting the calcium signaling in the cell systems. Calcium plays an important role in the adherence, replication and multiplication in the host cell. Once the virus enters the host cell, it utilizes the components of the host cell for replication and results in disruption of the host cell mechanisms including the calcium homeostasis thus altering the signal transduction in the host cell for survival and multiplication of the virus.
- The various host cell calcium channels and pumps including different voltage gated calcium channels, store operated channels, receptor operated channels, transient receptor potential ion channels and Calcium-ATPase etc. mediate the mobilization of secondary metabolite calcium across the plasma membranes and subcellular organelles thus modulating the intracellular free calcium. The intracellular calcium and the calcium channels play an important role in the viral-host interaction and viral pathogenesis in the host cell. These calcium channels and pumps are disrupted due to viral invasion leading to imbalance of intracellular calcium. As a result of which the viral growth is enhanced affecting the host cell morbidity.
- The effect of verapamil hydrochloride is analyzed in lipopolysaccharide-induced pathological damage in mouse. In order to analyze the effect of verapamil hydrochloride on inflammation and oxidative stress, the levels of interleukin-1b IL-1b), Tumor Necrosis Factor (TNF-α) and Monocyte Chemoattractant Protein-1 (MCP-1) in serum and activities of Myeloperoxidase (MPO), Lactate Dehydrogenase (LDH) and Superoxide Dismutase (SOD), Malondialdehyde (MDA) content and lung wet/dry ratio.
-
FIG. 4 illustrates the effect of verapamil hydrochloride against lipopolysaccharide-induced pathological damage in mice. Mice are treated with 5 mg/kg of lipopolysaccharide. Two hours later, mice are treated with verapamil hydrochloride at a concentration of 10mg,/kg, and saline as control and observed for 10 hours. The levels of IN-1b, TNF-a, MCP-1 in serum is analyzed using ELISA and activities of MPO, LDH, SOD and MDA is analyzed in addition to lung wet/dry ratio. The effect of verapamil hydrochloride on total cells, macrophages and neutrophils in Bronchoalveolar Lavage Fluid (BALF) is also analyzed. - The results indicated that verapamil hydrochloride exhibited anti-inflammatory activity by reducing the serum levels of IN-1b, TNF-a, MCP-1 and total cells, macrophages and neutrophils in BALF. In addition, the activities of MPO. LDH, SOD and MDA levels are reduced in lung tissue in response to verapamil hydrochloride. This indicates the anti-inflammatory and antioxidant activity of verapamil hydrochloride in mice.
- Verapamil hydrochloride is analyzed for antiviral activity in patients with Chronic obstructive pulmonary disease (COPD). A double-blind placebo trial is conducted to analyze the effect of verapamil hydrochloride in patients admitted in Intensive Care Unit (ICU). Verapamil hydrochloride is administered as nasal spray and saline as placebo. The results indicated that verapamil hydrochloride increased oxygen saturation from 91.2±12.15 to 95.75±14.57 in patients after inhalation. Verapamil hydrochloride also improved correction of blood pH, blood oxygen pressure and oxygen ratio by maintaining high concentration in alveolar space and dilating the pulmonary vasculature selectivity. This indicates that verapamil hydrochloride is safe and does not induce any adverse effects in patients with COPD.
- According to another embodiment of the invention, verapamil hydrochloride is administered through pulmonary administration or inhalation using a nasal spray. The efficacy of a drug varies with the mode of administration and the drug may require more time to reach the site of action or may alter its efficacy while in the blood stream. The pharmacokinetics and the pharmacodynamics of the drug plays an important role in determining the efficacy of the drug. Hence, the mode of administration is very critical. Calcium channel blockers are administered. through pulmonary route, which directly targets the lung where the severity of the infection is high.
- SARS-COV2 viral infection results in the respiratory illness, breathing complications and pneumonia like symptoms affecting the lungs of a patient. Hence, direct pulmonary administration has an advantage for effective drug delivery without passing through the blood stream for a long time and decreasing the dosage due to direct administration.
- The pulmonary administration or inhalation of calcium channel blockers is achieved using unique drug delivery system such as inhalers or nebulizers. In addition to nasal spray, the invention can also expand to different types of inhalers such as pressurized metered dose inhalers, dry powder inhalers, multi-dose liquid inhalers and soft-mist inhalers for pulmonary administration. Similarly, small-volume nebulizer (SVN), breath-actuated jet nebulizer, vibrating mesh nebulizer, jet nebulizer with virtual valve technology, perforated oscillating membrane, deep tube oral spray are effective in delivering the calcium channel blockers as monotherapy or in combination for the treatment of COVID-19.
- The inhalers and nebulizers are simple and effective in pulmonary administration with lower dose requirement of drug. The pulmonary administration results in delivering precise and consistent doses to a targeted region in the lungs and maintain the stability of the delivered drugs.
- Even though the calcium channel blockers are effective in inhibiting the mobility of intracellular calcium by disrupting the calcium channel blockers, the antiviral activity against SARS-CoV-2 varies with the type of calcium channel blocker.
- The pulomary administration of the calcium channel blockers or antagonists requires only low dose of the drug due to its local pharmacological action in lungs compared to oral or any other route of administration. The pulomary administration is also associated with improved tolerance, patient compliance and also with effective viral eradication.
- The formulation of verapamil hydrochloride is administered as nasal spray with a concentration in the range between 15 mg/L to 20 mg/mL. However, addition into the nasal spray bottle the actuator has the ability to deliver less concentration of the drug i.e. 2.5 mg/actuation or spray. The nasal spray has an ability to deliver up to 140 ul of the solution and the concentration administered is 2.5 mg/125 ul.
- The nasal spray of the formulation of the present invention is administrated through a spray device. The spray device has capability of administering dose volume in the range between 50 μl to 140 μl of the formulation with a droplet size less than 10 μm as tested by laser diffraction method.
- The nasal spray of verapamil hydrochloride reduces the dose requirement as targeted delivery in nose which allows the entry of the virus and passage through upper respiratory and then lower respiratory tract. The nasal spray is also associated with ease of administration, improved patient compliance, self-administration without requirement of health professional and. is also cost-effective.
- The formulation of the invention may be useful as add-on therapy to the recommended standard of care for the patients who are moderately severe thus improving the disease outcome in patients. The treatment may be administered to patients who are tested positive for SARS-COV-2 virus at an early stage as well as those who have serious pneumonia like complications leading to Acute Respiratory Distress Syndrome (ARDS).
Claims (10)
1. A formulation for treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) induced Coronavirus Disease 2019 (COVID-19), the formulation comprises:
a. verapamil hydrochloride at a concentration in the range between 15 mg/mL and 25 mg/mL;
b. sodium chloride at a concentration of 625 mg/mL, and
c. distilled water at a volume between q.s. to 1 mL
2. The formulation as claimed in claim 1 , wherein the formulation with a concentration of verapamil hydrochloride at 20.0 mg/mL at pH 4.09 and 60° C. is stable for 33 days.
3. The formulation as claimed in claim 1 , wherein the formulation inhibited Ribonucleic acid (RNA) replication of SARS-COV-2 in human liver cell line.
4. The formulation as claimed in claim 1 , wherein the formulation inhibited calcium channel by disrupting the movement of calcium thus halting the calcium signaling.
5. The formulation as claimed in claim 1 , wherein verapamil hydrochloride at a concentration of 10 mg/kg inhibited the levels of interleukin-1b (IL-)b), Tumor Necrosis Factor (TNF-a) and Monocyte Chemoattractant Protein-1 (MCP-1) in serum and activities of Myeloperoxidase (MPO), Lactate Dehydrogenase (LDH) and Superoxide Dismutase (SOD), Malondialdehyde (MDA) content and lung wet/dry ratio in lipopolysaccharide-induced pathological damage in mouse.
6. The formulation as claimed in claim 1 , wherein verapamil hydrochloride exhibited antiviral activity in Chronic obstructive pulmonary disease (COPD).
7. The formulation as claimed in claim 1 , wherein the formulation is administered as pulmonary delivery in the form of a nasal spray.
8. The formulation as claimed in claim 1 , wherein the formulation is administered as pulmonary delivery through inhalation or nebulization.
9. The formulation as claimed in claim 1 , wherein the formulation is administered through a spray device.
10. The formulation as claimed in claim 1 , wherein the spray device has the ability to deliver less concentration of verapamil hydrochloride i.e. 2.5 mg/actuation or spray.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/234,112 US20210330631A1 (en) | 2020-04-28 | 2021-04-19 | Formulation of calcium channel blockers for treatment of sars-cov-2 induced covid-19 and other respiratory viruses through pulmonary delivery |
US18/304,306 US11938110B2 (en) | 2020-04-28 | 2023-04-20 | Use of verapamil for the treatment of SARS-Cov-2 induced COVID-19 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063016595P | 2020-04-28 | 2020-04-28 | |
US17/234,112 US20210330631A1 (en) | 2020-04-28 | 2021-04-19 | Formulation of calcium channel blockers for treatment of sars-cov-2 induced covid-19 and other respiratory viruses through pulmonary delivery |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/304,306 Continuation US11938110B2 (en) | 2020-04-28 | 2023-04-20 | Use of verapamil for the treatment of SARS-Cov-2 induced COVID-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210330631A1 true US20210330631A1 (en) | 2021-10-28 |
Family
ID=78221448
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/234,112 Pending US20210330631A1 (en) | 2020-04-28 | 2021-04-19 | Formulation of calcium channel blockers for treatment of sars-cov-2 induced covid-19 and other respiratory viruses through pulmonary delivery |
US18/304,306 Active US11938110B2 (en) | 2020-04-28 | 2023-04-20 | Use of verapamil for the treatment of SARS-Cov-2 induced COVID-19 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/304,306 Active US11938110B2 (en) | 2020-04-28 | 2023-04-20 | Use of verapamil for the treatment of SARS-Cov-2 induced COVID-19 |
Country Status (1)
Country | Link |
---|---|
US (2) | US20210330631A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040167117A1 (en) * | 2003-02-18 | 2004-08-26 | Compellis Pharmaceuticals | Inhibition of olfactory neurosensory function to treat eating disorders and obesity |
US20050245502A1 (en) * | 1999-08-23 | 2005-11-03 | Phoenix Biosciences | Treatments for viral infections |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6190691B1 (en) * | 1994-04-12 | 2001-02-20 | Adolor Corporation | Methods for treating inflammatory conditions |
US7335186B2 (en) * | 1998-03-13 | 2008-02-26 | Alexander George Brian O'Neil | Patient controlled drug delivery device |
US20080038363A1 (en) * | 2001-05-24 | 2008-02-14 | Zaffaroni Alejandro C | Aerosol delivery system and uses thereof |
US20050191245A1 (en) | 2004-02-27 | 2005-09-01 | Adams Christopher P. | Nasal administration of calcium channel, blockers for treatment of hypertension and other cardiovascular disorders |
WO2021183463A1 (en) * | 2020-03-09 | 2021-09-16 | President And Fellows Of Harvard College | Compositions and methods for treating coronavirus |
WO2021181279A1 (en) * | 2020-03-09 | 2021-09-16 | Enzychem Lifesciences Corporation | Compositions and methods for treating covid-19 infections and/or symptoms thereof |
-
2021
- 2021-04-19 US US17/234,112 patent/US20210330631A1/en active Pending
-
2023
- 2023-04-20 US US18/304,306 patent/US11938110B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050245502A1 (en) * | 1999-08-23 | 2005-11-03 | Phoenix Biosciences | Treatments for viral infections |
US20040167117A1 (en) * | 2003-02-18 | 2004-08-26 | Compellis Pharmaceuticals | Inhibition of olfactory neurosensory function to treat eating disorders and obesity |
Non-Patent Citations (3)
Title |
---|
Crowley, "Nasal Solutions" in: "Solutions, Emulsions, Suspensions, and Extracts" in: Hendrickson, Remington: The Science and Practice of Pharmacy, 21st ed., Lippincott Williams & Wilkins, 2005, pp. 752-753. (Year: 2005) * |
Gupta, "Quantitation and stability of verapamil hydrochloride using high-performance liquid chromatography", 1985, Drug Development and Industrial Pharmacy, 11(8), pages 1497-1506. (Year: 1985) * |
Zhang et al., "Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension", published 22 December 2020, Cell Discovery, vol. 6, no. 96, pages 1-12. (Year: 2020) * |
Also Published As
Publication number | Publication date |
---|---|
US11938110B2 (en) | 2024-03-26 |
US20230255924A1 (en) | 2023-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Smee et al. | Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N | |
Hayashi et al. | Inhibitory effect of cinnamaldehyde, derived from Cinnamomi cortex, on the growth of influenza A/PR/8 virus in vitro and in vivo | |
JP7225103B2 (en) | Cannabinoid-containing complex mixtures for treating neurodegenerative diseases | |
Lee et al. | Targeting the host or the virus: current and novel concepts for antiviral approaches against influenza virus infection | |
US9492413B2 (en) | Use of salt of an acetylsalicylic acid for the treatment of viral infections | |
Palit et al. | Phytopharmaceuticals mediated Furin and TMPRSS2 receptor blocking: can it be a potential therapeutic option for Covid-19? | |
Alkotaji | Azithromycin and ambroxol as potential pharmacotherapy for SARS-CoV-2 | |
CN112912074A (en) | EGCG-palmitate compositions and methods of use thereof | |
Shin et al. | Comparison of anti-influenza virus activity and pharmacokinetics of oseltamivir free base and oseltamivir phosphate | |
WO2020241759A1 (en) | Prophylactic and/or therapeutic agent for influenza virus infection or corona virus infection | |
Dinda et al. | Some natural compounds and their analogues having potent anti-SARS-CoV-2 and anti-proteases activities as lead molecules in drug discovery for COVID-19 | |
Lejal et al. | Turning off NADPH oxidase-2 by impeding p67phox activation in infected mouse macrophages reduced viral entry and inflammation | |
US20210069098A1 (en) | Ribavirin perflubron emulsion composition for treating viral diseases | |
Döring et al. | Insights into the direct anti-influenza virus mode of action of Rhodiola rosea | |
Ganguly et al. | In silico analysis reveals the inhibitory potential of madecassic acid against entry factors of SARS-CoV-2 | |
US11938110B2 (en) | Use of verapamil for the treatment of SARS-Cov-2 induced COVID-19 | |
EP3934653B1 (en) | Azelastine as antiviral treatment | |
WO2023075898A1 (en) | Antiviral & virucidal lung nebulizer compositions | |
WO2007093635A2 (en) | Proteasom or ups inhibitor for treating infections with influenza viruses | |
Yang et al. | Exploration of the mechanisms of Callicarpa nudiflora Hook. et Arn against influenza A virus (H1N1) infection | |
He et al. | Anti-influenza drug screening and inhibition of apigetrin on influenza A virus replication via TLR4 and autophagy pathways | |
US20230075092A1 (en) | Combination of diltiazem and viral polymerase inhibitors | |
SE545271C2 (en) | Pharmaceutical composition for treatment of viral infections caused by enveloped viruses | |
CN115998877A (en) | Application of CMPK2 inhibitor in preparation of medicine for preventing and treating respiratory syncytial virus infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: JADHAV, MANOJ PURUSHOTTAM, NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DEVARAKONDA, RAMAKRISHNA;REEL/FRAME:055960/0354 Effective date: 20210414 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |